InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Wednesday. The brokerage issued a sell rating on the stock.

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $2.90 on Wednesday. The firm has a market cap of $72.30 million, a price-to-earnings ratio of -3.82 and a beta of 0.96. The firm has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.50. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The firm had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. As a group, research analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

Several institutional investors have recently modified their holdings of the stock. Rosalind Advisors Inc. increased its stake in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares in the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in InspireMD during the first quarter worth about $71,000. Finally, McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD during the 4th quarter valued at about $28,000. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.